Review Article

Nipah Virus: A Hidden and Continuous Threat to Humankind

Authors
Dr Kumar S Abhishek¹, Dr Tirtha Priya*²
¹Senior Resident, Department of Microbiology, All India Institute of Medical Sciences, Jodhpur, Rajasthan
Email: get.abhi1904@gmail.com, Mobile no.: +91 9431336454
²Intern, KLE Vishwanath Katti Institute of Dental Sciences, Belgaum, Karnataka, India
*Corresponding Author
Dr Tirtha Priya
Email: priya.tirtha20@gmail.com, Mobile no.: +91 8789366349

Abstract
Nipah virus, a member of family Paramyxoviridae, genus Henipavirus causes acute and severe respiratory illness and encephalitis in humans. The primary source of infection is through infected pigs and bats. Virus was first isolated in 1999 post 1998 outbreak in Malaysia, where pigs were the primary source of infection. Unlike Malaysia, fruit bats of family Pteropodidae were the main reservoir in Bangladesh and India. Several outbreaks have been reported from Bangladesh and India in past 20 years. Most of the infections are associated with ingestion of date palm sap contaminated by bats and even human to human transmission is also known. Viral isolation, Nucleic acid amplification tests and serology are the main diagnostic methods. Several ELISA based tests are available for serological diagnosis. As so far no approved vaccine or effective antiviral drugs are available, the mainstays of management relies on preventive and supportive management.

Keywords: Henipavirus, Pteropus bats, Encephalitis, Outbreak, ELISA, Vaccine.

Introduction
Nipah virus a member of family Paramyxoviridae closely resembles Hendra virus, the two recognized spices of genus Henipavirus. The first reported outbreak occurred during September 1998 – April 1999 in Malaysia (¹). India has also witnessed few outbreaks during 2001 and 2007 in West Bengal and recently in Kozhikode district of Kerala (2018). The first viral isolation was from the Kampung Sungai Nipah (Nipah River Village) and therefore named as Nipah Virus (NiV) (²). Nipah virus is mostly zoonotic and the main sources of infection are pigs and bats, though human to human transmission is also known. The incubation period is highly variable ranging from few days to months, with 90% within two weeks³. Initially the people develops influenza like symptoms like high grade fever, sore throat, headache, myalgia and weakness followed by impaired consciousness and spatial perception accompanied by nausea and vomiting suggestive of acute encephalitis³. The mortality rate during Malaysian outbreak was around 40% while during Bangladesh outbreak approached to more 70% which was due to more respiratory involvement (⁴).
Epidemiology
The first outbreak of Nipah virus occurred during 1998-1999 among the pig farm workers in the north west part of Malaysia\(^{(1,2)}\). Pig farming and agriculture have been directly implicated in the transmission of Nipah virus. Pigs by consuming the bat fed fruits became infected with Nipah virus, which eventually spread to the pig farm workers. During outbreak in Malaysia, out of 283 cases of viral encephalitis, 265 cases were identified to be acute Nipah encephalitis on the basis of laboratory investigations. Out of these 265 cases, 105 people lost their life accounting for 40% mortality. More than 80% of cases occurred in males and majority of them were directly involved in pig-farming\(^{(5)}\). Singapore witnessed Nipah virus outbreak in 1999 accounting for 11 cases with one death, probably because of importation of infected pigs from Malaysia. Various outbreaks because of Nipah virus is summarized in Table 1\(^{(6,7)}\).

Bangladesh is endemic for Nipah virus outbreaks, particularly in districts where date palm sap is produced. Transmission occurs by the consumption of raw date palm sap. *Pteropus* fruit bats, the reservoir of Nipah virus, visit the date palm and contaminates the sap by licking and urinating into the collection pots\(^{(8)}\). In Bangladesh Nipah virus outbreak occurs almost every year with more than 75% mortality rate. In India the disease was reported in humans without involvement of pigs. The two outbreaks that occurred in West Bengal during 2001 and 2007 in Siliguri and Nadia districts respectively accounted for more than 75% mortality. *Pteropus* species fruit bats crossing the border were the probable source of Nipah virus in these districts. Recently three deaths due to Nipah virus infection were reported on 19 May 2018 from Kozhikode District of Kerala and a fourth death of a health care worker who was involved in providing medical care to the deceased. Laboratory testing at National Institute of Virology, Pune confirmed positive for Nipah virus in three out of four deaths by RT-PCR and IgM ELISA for Nipah virus. Until 28 May 2018, 15 people have been tested positive for Nipah virus from Kozhikode and Malappuram districts of Kerala. Out of these 15 cases, thirteen already lost their life. This is the first reported outbreak from Kerala and third from all over the country\(^{(9)}\).

Table 1: Nipah virus Outbreaks

| Year | Country | Cases | Deaths | Case Fatality |
|------|---------|-------|--------|--------------|
| 1998 | Malaysia | 265   | 105    | 40%          |
| 1999 | Singapore | 11    | 1      | 9%           |
| 2001 | Bangladesh | 13    | 9      | 69%          |
| 2001 | India    | 66    | 49     | 74%          |
| 2003 | Bangladesh | 12    | 8      | 67%          |
| 2004 | Bangladesh | 67    | 50     | 75%          |
| 2005 | Bangladesh | 12    | 11     | 92%          |
| 2007 | Bangladesh | 18    | 9      | 50%          |
| 2007 | India    | 5     | 5      | 100%         |
| 2008 | Bangladesh | 11    | 9      | 82%          |
| 2009 | Bangladesh | 4     | 1      | 25%          |
| 2010 | Bangladesh | 16    | 14     | 88%          |
| 2011 | Bangladesh | 44    | 40     | 91%          |
| 2012 | Bangladesh | 12    | 10     | 83%          |
| 2013 | Bangladesh | 24    | 21     | 87%          |

The Virus
The Nipah virus is classified as:
**Subfamily:** Paramyxovirinae
**Family:** Paramyxoviridae
**Genus:** Henipavirus

The genus Henipavirus contains two most pathogenic viruses to humans namely Hendravirus and Nipah virus which were identified in 1994 and 1998 respectively\(^{(2)}\). Nipah virus is highly pathogenic and thus Biosafety Level-4 containment is required for dealing with live Nipah virus\(^{(10)}\). Nipah virus is closely related to Hendra virus, which caused lethal disease in horses and humans during 1994 in Australia. Morphologically, Nipah virus is similar to other paramyxoviruses with slightly larger genome. They are pleomorphic, spherical to filamentous with size ranging from 40 to 1900nm. Unlike other paramyxoviruses, Nipah virus lacks hemagglutinin and neuraminidase properties and contain a single layer of surface projections with an average length of 17nm\(^{(11)}\). The RNA genome consists of six genes N, P, M, F, G and L encoding for nucleoprotein,
phosphoprotein, matrix, fusion protein, glycoprotein and large RNA polymerase respectively\(^\text{(12)}\). Unlike the HN protein of other paramyxoviruses, G and F proteins of Nipah virus mediated viral entry into the host cells and antibodies produced against these protein neutralizes viral particles\(^\text{(13)}\). In addition to P protein, P gene also encodes for three other non-structural protein C, V and W, usually not required for viral replication but often serves as virulence factors\(^\text{(14)}\).

There are two major genetic lineage, Nipah virus-Malaysia (NiV-MY) with 18,246 nucleotides and Nipah virus- Bangladesh (NiV-BD) with 18,252 nucleotides genome length\(^\text{(11)}\). Functionally, the two strains are indistinguishable, but animal model studies have suggested certain differences in these strains. African green monkey model indicated that NiV-BD is more pathogenic with narrower window for passive antibody therapy than NiV-MY\(^\text{(15)}\). Similar study using ferret model showed increased oral shedding with more rapid onset and higher levels of viral replication in the respiratory tract of NiV-BD than NiV-MY\(^\text{(16,17)}\). These properties of NiV-BD explained the shorter incubation, more respiratory symptoms, human to human transmission and higher case fatality in cases from Bangladesh and India.

### Transmission

Members of paramyxoviruses are known to have a limited number of host range with rare interspecies transmission. Unlike other paramyxoviruses, Nipah virus uses highly conserved mammalian ephrinB2/B3 molecules as their entry receptors, thus displaying a wide species tropism along with interspecies transmission\(^\text{(18,19)}\). Fruit bats commonly known as flying foxes member of family Pteropodidae have been identified as the main reservoir for Nipahvirus. Bats primarily shed NiV via urinary route and capable of infecting humans directly or through pigs and horses as intermediate amplifier host\(^\text{(20)}\). During Malaysia outbreak, bats were assumed to introduce virus into the swine population by shedding viruses in their urine and saliva. Pigs while consuming fruits contaminated by bats acquired the viruses and then transmitted to the pig-farm workers. This was confirmed by the serological survey during 1998-99 outbreak of *Pteropus* bats, demonstrating positive antibodies for Nipah virus\(^\text{(21)}\). Two outbreaks in India and several outbreaks in Bangladesh between 2001 to 2013 did not show any involvement of pigs. Outbreak investigations in Bangladesh identified another routes of viral transmission which included climbing tree, consumption of raw date palm sap and contact with sick person or animals\(^\text{(22)}\). *Pteropus giganteus* (fruit bats) drinks the sap from the collecting pots at night and even contaminates the pot through their urine. Consumption of contaminated raw date palm sap transmits the virus to humans\(^\text{(23)}\). In India, the presence of Nipah virus RNA was detected from the liver homogenate of *P. giganteus* captured from Myanaguri, West Bengal\(^\text{(24)}\). In Siliguri, India, 75% of cases occurred among hospital staffs and visitors, strongly suggestive of human to human transmission within a health care setting\(^\text{(25)}\). Similarly approximately half of the patients in Bangladesh between 2001-2007 developed their disease following human to human transmission\(^\text{(20)}\).

### Pathogenesis

The incubation period of Nipah virus is highly variable from days to months, with more than 90% at 2 weeks or less\(^\text{(3)}\). Patients commonly presents with highgrade fever, dizziness, headache, vomiting with gradual development of severe encephalitis. Majority of them develops reduced level of consciousness and signs of brain stem dysfunctions in form of abnormal pupillary reflex, vasomotor changes, seizures and myoclonic jerks\(^\text{(3)}\). Respiratory involvement was rare during Malaysian outbreak, while two thirds cases from Bangladesh and India had respiratory
involvement and few of them even developed acute respiratory distress syndrome. These differences was may be because of two different strains of Nipah virus as discussed earlier.

**Respiratory Infection:** In humans, Nipah virus can be detected in the bronchial epithelium and are shed mainly in nasopharyngeal and tracheal secretions during the early phase of disease\(^{(26)}\). This accounts for the human to human transmission during the early phase of illness. Nipah virus leads to recruitment of immune cells by induction of inflammatory cytokines that can progress to an Acute Respiratory Distress Syndrome like disease\(^{(27)}\).

**Viremia:** Viremia usually develops late in disease when virus replicating in respiratory epithelium gain access to circulation and disseminate throughout the body leading to multi organ failure \(^{(28)}\).

**CNS Infection:** Nipah virus in human induces expression of pro-inflammatory cytokines (TNF-\(\alpha\) and IL-1\(\beta\)) which have been shown to increase blood brain barrier (BBB) permeability in addition to neural injury and death in animal models\(^{(27)}\). Disruption of BBB is by direct cytopathic effect of viral replication or indirect effect of TNF-\(\alpha\) and IL-1\(\beta\) expression is still doubtful. Several animal model experiments have shown direct entry of Nipah virus into CNS through the olfactory nerve. Nipah virus infects neurons through the cribriform plate extends into olfactory bulb and from there directly into CNS\(^{(29)}\).

**Autopsy Findings:** Pathological lesions were seen mainly in brain with disseminated microinfarction due to vasculitis induced thrombosis and direct neuronal involvement amongst victims from Malaysian outbreak. Similar vasculitis lesions were also seen in other organs like respiratory tract, heart and kidneys. Vasculitis in Nipah virus infection commonly involved small and medium sized vessels resulting into endothelial multinucleated syncytia formation and fibrinoid necrosis\(^{(30)}\).

**Diagnosis**

Nipah virus is highly pathogenic and thus for isolation and propagation, Biosafety Level-4 containment is needed\(^{(10)}\). It is a potential agent for bioterrorism and is listed as a category C agent by the Centers for Disease Control and Prevention \(^{(31)}\). Nipah virus infection can be diagnosed by various methods:

i. Viral Isolation

ii. Serology

iii. Molecular

**Viral Isolation:** Viral isolation can be performed using African green monkey kidney (Vero) and Rabbit kidney (RK-13) cell lines \(^{(32)}\). Viral growth is indicated by the appearance of cytopathic effects (CPE) within 3 days in form of large multinucleated syncytia formation containing viral antigen. Additional two 5-days passages are recommended if no CPE develops to confirm negative for Nipah virus. To characterize viral isolation and to look for cross reactivity within Henipaviruses, immunostaining and virus neutralization tests like plaque reduction, microtitre neutralization and immunoplaque assay are applied\(^{(32)}\).

**Serology**

**Antigen Detection:** Monoclonal antibody based antigen capture ELISA. Polyclonal antibodies derived from rabbit by injecting NiV-G protein was used for development of antigen capture sandwich ELISA.

**Antibody Detection:** ELISAs are the most common serological assay. Infected cell lysate antigen coated ELISAs are used to demonstrate circulating IgM/IgG Antibodies.

**Molecular**

**RT-PCR:** Reverse Transcriptase Polymerase chain reaction

**Real Time RT-PCR**

**Duplex Nested RT-PCR**

Confirmed by the sequencing of the amplified products. In Fatal cases, post autopsy immunohistochemistry is performed to confirm a diagnosis.
In India, NIV, Pune has got the preparedness for the diagnosis of Nipah virus whenever a suspected event occurs in the country.

Treatment and Prevention
The treatment options in form of antiviral drugs are limited. Though Ribavirin has been shown to be effective in vitro but their trials in human till date is inconclusive and clinical usefulness remains uncertain. In ferret model passive immunization, using Human monoclonal antibody against Nipah-G glycoprotein has been found to be effective. Thus preventive strategies are the mainstay of controlling Nipah virus infection. Important preventive measures includes:

a) Preventing farm animals from acquiring Nipah virus by eating fruits contaminated by bats.

b) Avoid overcrowding of farm animals to prevent rapid spread of disease and animals should not be kept near fruit trees that attracts fruit bats.

c) Avoid unnecessary contact with sick animals.

d) Avoid consumption of raw date palm sap.

e) Use of physical barriers to prevent bats from accessing and contaminating sap.

f) Use of proper physical barrier protection while handling a suspected case of Nipah virus.

Vaccines
In several pre-clinical studies, number of vaccine candidates have been found to be capable of providing complete protection against Nipah virus in small animal and non-human primate models. Protection was demonstrated in hamster, ferret and African green monkey using a Vesicular stomatitis virus candidate vaccines. Hendra G protein subunit vaccine producing cross-protection against Hendra virus and Nipah virus has been used recently in Australia to protect horses against Hendra virus and offers great potential for protection in humans against other Henipaviruses.

Vaccination should also be extended to cover farm animals especially pigs in areas where Nipah virus is endemic.

WHO has declared Nipah virus to be a priority pathogen, and pharmaceutical companies may be funded to carry out trials in underdeveloped countries where affording medication and vaccination is a troublesome task. Coalition for Epidemic Preparedness Innovations (CEPI) an International coalition of governments and pharmaceutical companies was formed in January 2017 to develop safe, effective and affordable vaccines for diseases with pandemic potential including Nipah virus.

Conclusion
The emergence of new virus called Nipah virus twenty years ago with potential to cause severe fatal neurological and respiratory complications leading to death both in humans and animals, and it continues to be like a hidden threat to re-emerge. Several outbreaks in past twenty years especially in Bangladesh and India had led to severe fatal outcome. Pteropus bats, which is widespread beyond these endemic regions constitutes a potential threat for outbreaks to occur in new regions.

References
1. Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PSK, et.al. Fatal encephalitis due to Nipah virus among pig farmers in Malaysia. Lancet. 1999;354:1257–9.

2. Chua KB, Bellini WJ, Rota PA, Harcourt BH, TaminA, et.al. Nipah virus: a recently emergent deadly paramyxovirus. Science. 2000; 288:1432–1435.

3. Goh KJ, Tan CT, Chew NK, Tan PS, Kamarulzaman A, et.al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med. 2000;342:1229–1235.

4. WHO | World Health Organization. Retrieved June 06, 2018, from
http://www.who.int/news-room/fact-sheets/detail/nipah-virus.html.

5. Ministry of Health Malaysia. Cabinet Report: JE / Nipah Outbreak In Malaysia. 2001; Volume 1: 1-133.

6. World Health Organization, Regional Office for South-East Asia (SEARO) (2012) Nipah virus outbreaks in the WHO South-East Asia Region.

7. Institute of Epidemiology, Disease Control and Research (2013) Nipah Infection in 2013.

8. Khan MS, et al. Use of infrared camera to understand bats’ access to date palm sap: Implications for preventing Nipah virus transmission. EcoHealth. 2010;7:517–525.

9. WHO | World Health Organization. Retrieved June 06, 2018, from http://www.who.int/csr/don/31-may-2018-nipah-virus-india/en/

10. Lo MK, Rota PA. Emergence of Nipah virus, a highly pathogenic Paramyxovirus. J Clin Virol. 2008;43:396–400.

11. Wang LF, Mackenzie JS, Broder CC. 2013. Henipaviruses, p 286 –313. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.

12. Chan YP, Chua KB, Koh CL, Lim ME, Lam SK. Complete nucleotide sequences of Nipah virus isolates from Malaysia. J Gen Virol. 2001;82:2151–5.

13. Tamin A, Harcourt BH, Ksiazek TG, Rollin PE, Bellini WJ, Rota PA. Functional properties of the fusion and attachment glycoproteins of Nipah virus. Virology. 2002;296(1):190–200.

14. Harcourt BH, Tamin A, Halpin K, Ksiazek TG, Rollin PE, Bellini WJ, Rota PA. Molecular characterization of the polymerase gene and genomic termini of Nipah virus. Virology. 2001;287:192–201.

15. Mire CE, Satterfield BA, Geisbert JB, Agans KN, Borisevich V, Yan L, Chan YP, Cross RW, Fenton KA, Broder CC, Geisbert TW. Pathogenic differences between Nipah virus Bangladesh and Malaysia strains in primates: implications for antibody therapy. Sci Rep. 2016;6:30916.

16. Clayton BA, Middleton D, Bergfeld J, Haining J, Arkinstall R, Wang L, Marsh GA. Transmission routes for Nipah virus from Malaysia and Bangladesh. Emerg Infect Dis. 2012;18:1983–1993.

17. Clayton BA, Middleton D, Arkinstall R, Frazer L, Wang LF, Marsh GA. The nature of exposure drives transmission of Nipah viruses from Malaysia and Bangladesh in ferrets. PLoSNegl Trop Dis. 2016;10:e0004775.

18. Negrete OA, Wolf MC, Aguilar HC, Enterlein S, Wang W, et.al. Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog. 2006 2:e7.

19. Bonaparte MI, Dimitrov AS, Bossart KN, Cramer G, Mungall BA, et.al. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A. 2005;102:10652–10657.

20. Luby SP, Gurley ES, Hossain MJ. Transmission of human infection with Nipah virus. Clin Infect Dis. 2009;49:1743–1748.

21. Olson J, Rupprecht CE, Rollin PE, An US, Niezgoda M, et.al. Antibodies to Nipah-Like virus in Bats (Pteropuslylei), Cambodia. Emerg Infect Dis. 2002;8(9):987–8.

22. Montgomery J, Hossain MJ, Gurley E, Carroll DS, Croisier A, et.al. Risk factors for Nipah virus infection in Bangladesh. Emerg Infect Dis. 2008;14(10):1526–32.

23. Luby SP, Rahman M, Hossain MJ, Blum LS, Husain MM, et.al. Foodborne Transmission of Nipah Virus, Bangladesh. Emerg Infect Dis. 2006;12:1888–94.

24. Yadav PD, Raut CG, Shete AM, Mishra AC, Towner JS, et.al. Detection of Nipah
25. Chadha MS, Comer JA, Lowe L, Rota PA, Rollin PE, et al. Nipah virus-associated encephalitis outbreak, Siliguri, India. Emerg Infect Dis. 2006;12(2):235–40.

26. Chua KB, Lam SK, Goh KJ, Hooi PS, Ksiazek TG, et al. The presence of Nipah virus in respiratory secretions and urine of patients during an outbreak of Nipah virus encephalitis in Malaysia. J Infect. 2001;42:40-43.

27. Rockx, Brining D, Kramer J, Callison J, Ebihara H, et al. Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection. J Virol. 2011;8:7658-7671.

28. Selvey LA, Wells RM, McCormack JG, Ansford AJ, Murray K, et al. Infection of humans and horses by a newly described morbillivirus. Med J Aust. 1995;162:642-645.

29. Munster VJ, Prescott JB, Bushmaker T, Long D, Rosenke R, et al. Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route. Sci Rep. 2012;2:736.

30. Ang BSP, Lim TCC, Wang L. Nipah virus infection. J Clin Microbiol. 2018;56:e01875-17.

31. Centers for Disease Control and Prevention. Bioterrorism agents. Centers for Disease Control and Prevention, Atlanta, GA. 2018

32. World Organisation for Animal Health (Office International des Épizooties: OIE) (2010) Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, OIE, Paris, Hendra and Nipah virus diseases, Chapter 2.9.6. p. 3-9.

33. CDC | Center for Disease Control. Retrieved June 07, 2018, from https://www.cdc.gov/vhf/nipah/index.html

34. Satterfield BA, Dawes BE, Milligan GN. Status of vaccine research and development of vaccines for Nipah virus. Vaccine. 2016;34:2971–2975.